Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion ...

Yes, you can get your flu and COVID-19 shots at the same time. Don't call them boosters -- they're not just another dose of ...

Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...

Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...

Even though the company surprised analysts by reporting net income of $13 million (up from a $3.63 billion net loss in Q3 ...

Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax shot in a head-to-head clinical trial.

The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...

Moderna (NASDAQ:MRNA – Get Free Report) had its price objective dropped by research analysts at Barclays from $125.00 to $111 ...

which accused the company of misusing the school's innovations to develop its blockbuster COVID-19 vaccine Spikevax. British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in ...

Moderna crushed third-quarter expectations on Thursday and turned around a surprise profit. But Moderna stock pulled back ...